Evidence map›Paper›PMID 32867069›Full record

ArticleInternational journal of molecular sciences2020

Tumor Suppressor Role of hsa-miR-193a-3p and -5p in Cutaneous Melanoma.

Beatrice Polini, Sara Carpi, Stefano Doccini, Valentina Citi, Alma Martelli, Sara Feola, Filippo Maria Santorelli, Vincenzo Cerullo, Antonella Romanini, Paola Nieri

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. The role of hsa-miR-193a-5p as an important factor for control of inositol in alopecia areata.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Beatrice PoliniDepartment of Pharmacy, University of Pisa, 56126 Pisa, Italy.
Sara CarpiDepartment of Pharmacy, University of Pisa, 56126 Pisa, Italy.
Stefano DocciniMolecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit, IRCCS Stella Maris Foundation, 56128 Pisa, Italy.
Valentina CitiDepartment of Pharmacy, University of Pisa, 56126 Pisa, Italy.
Alma MartelliDepartment of Pharmacy, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-2090-7107
Sara FeolaLaboratory of ImmunoViroTherapy (IVTLab), Drug Research Program (DRP), Translation Immunology Program (TRIMM), iCAN Precision Cancer Medicine, University of Helsinki, 00014 Helsinki, Finland.ORCID 0000-0002-4012-4310
Filippo Maria SantorelliMolecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit, IRCCS Stella Maris Foundation, 56128 Pisa, Italy.ORCID 0000-0002-1359-9062
Vincenzo CerulloLaboratory of ImmunoViroTherapy (IVTLab), Drug Research Program (DRP), Translation Immunology Program (TRIMM), iCAN Precision Cancer Medicine, University of Helsinki, 00014 Helsinki, Finland.ORCID 0000-0003-4901-3796
Antonella RomaniniMedical Oncology Unit, Azienda Ospedaliero-Universitaria Pisana, 56126 Pisa, Italy.
Paola NieriDepartment of Pharmacy, University of Pisa, 56126 Pisa, Italy.
University of Pisa · ITFondazione Stella Maris · ITUniversity of Helsinki · FIAzienda Ospedaliera Universitaria Pisana · IT

Funding

Associazione contro il melanoma (ACM) ONLUS 20171801
6 · The paper itself

Abstract

backgroundRemarkable deregulation of several microRNAs (miRNAs) is demonstrated in cutaneous melanoma. hsa-miR-193a-3p is reported to be under-expressed in tissues and in plasma of melanoma patients, but the role of both miR-193a arms in melanoma is not known yet.

methodsAfter observing the reduced levels of miR-193a arms in plasma exosomes of melanoma patients, the effects of hsa-miR-193a-3p and -5p transfection in cutaneous melanoma cell lines are investigated.

resultsIn melanoma cell lines A375, 501Mel, and MeWo, the ectopic over-expression of miR-193a arms significantly reduced cell viability as well as the expression of genes involved in proliferation (ERBB2, KRAS, PIK3R3, and MTOR) and apoptosis (MCL1 and NUSAP1). These functional features were accompanied by a significant downregulation of Akt and Erk pathways and a strong increase in the apoptotic process. Since in silico databases revealed TROY, an orphan member of the tumor necrosis receptor family, as a potential direct target of miR-193a-5p, this possibility was investigated using the luciferase assay and excluded by our results.

conclusionsOur results underline a relevant role of miR-193a, both -3p and -5p, as tumor suppressors clarifying the intracellular mechanisms involved and suggesting that their ectopic over-expression could represent a novel treatment for cutaneous melanoma patients.

Indexed as

Down-Regulation3' Untranslated RegionsCase-Control StudiesCell Line, TumorCell ProliferationCell SurvivalCutaneous Malignant MelanomaExosomesFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMaleMelanomaMicroRNAsMiddle Aged3' Untranslated RegionsMicroRNAsMIRN193 microRNA, humancutaneous melanomamicroRNAmiR-193a-3pmiR-193a-5ptumor suppressor

Identifiers

PMID32867069
PMCPMC7503447
OpenAlexW3081013320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.